...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of stroke and cerebrovascular diseases: The official journal of National Stroke Association >Efficacy of NeuroFlo device in treatment of patients with atrial fibrillation
【24h】

Efficacy of NeuroFlo device in treatment of patients with atrial fibrillation

机译：NeuroFlo装置在房颤患者治疗中的功效

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Atrial fibrillation (AF) is a well-established independent risk factor for stroke. We examined cerebral blood flow augmentation in the treatment of acute ischemic stroke (AIS) in patients with AF by performing secondary analysis of data from the Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke (SENTIS) trial, a randomized controlled trial evaluating NeuroFlo treatment in stroke patients within 14 hours of symptom onset. We report subgroup analyses of outcomes in SENTIS patients with a history or new diagnosis of AF. Among patients with AF, those treated with NeuroFlo demonstrated significant improvement over those not treated for multiple end points: global efficacy end point (P =.030), modified Rankin Scale (mRS) score 0-2 versus 3-6 (P =.029), and stroke-related mortality (P =.015). There was a significant improvement in global end point for those aged 60 years or older (P =.042) and 80 years or older (P =.017), with a trend toward improvement for age 70 years or older (P =.055), and significant improvement in those who achieved good outcomes (mRS score 0-2 versus 3-6) at age 60 years or older (P =.038), 70 years or older (P =.022), and 80 years or older (P =.008). NeuroFlo treatment in stroke patients with AF resulted in significantly better outcomes compared with nontreated patients with AF. Collateral flow recruitment, maintenance of cerebral blood flow around stroke core, and improvement of penumbral blood flow are potential mechanisms for these improved outcomes. NeuroFlo may represent a valid therapeutic option for patients with AF and AIS, and therefore, future trials of the device are warranted.
机译：心房颤动（AF）是公认的中风独立危险因素。我们通过对NeuroFlo缺血性卒中技术（SENTIS）试验的安全性和有效性进行数据的二次分析，检查了脑血管血流量增加对房颤患者的急性缺血性卒中（AIS）的治疗，该数据是一项随机对照试验，评估了NeuroFlo治疗于中风患者症状发作后14小时内。我们报告了有AF史或AF新诊断的SENTIS患者结局的亚组分析。在患有AF的患者中，用NeuroFlo治疗的患者与未治疗多个终点的患者相比有显着改善：总体疗效终点（P = .030），改良的Rankin量表（mRS）评分0-2对3-6（P =。 029），以及与中风相关的死亡率（P = .015）。对于60岁以上（P = .042）和80岁以上（P = .017）的人群，全球终点显着改善，而70岁以上的人群（P = .055）有改善的趋势。 ），并且在60岁或以上（P = .038），70岁或以上（P = .022）和80岁或以上的患者中获得良好结局（mRS评分0-2对3-6）的显着改善（P = .008）。与未经治疗的房颤患者相比，NeuroFlo治疗中风房颤患者的转归明显更好。补充侧支血流，维持中风核心周围的脑血流以及改善半影血流是这些改善预后的潜在机制。 NeuroFlo可能代表AF和AIS患者的有效治疗选择，因此，有必要对该设备进行进一步的试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号